Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
As of close of business last night, Celldex Therapeutics Inc’s stock clocked out at $19.97, up 0.96% from its previous closing price of $19.78. In other words, the price has increased by $0.96 from its previous closing price. On the day, 0.71 million shares were traded.
Ratios:
To gain a deeper understanding of CLDX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 21.67 and its Current Ratio is at 21.67. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Canaccord Genuity on April 28, 2025, initiated with a Buy rating and assigned the stock a target price of $64.
On March 20, 2025, Morgan Stanley started tracking the stock assigning a Overweight rating and target price of $46.
On February 13, 2025, UBS started tracking the stock assigning a Buy rating and target price of $44.UBS initiated its Buy rating on February 13, 2025, with a $44 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Nov 11 ’24 when Marucci Anthony S bought 11,500 shares for $26.82 per share. The transaction valued at 308,430 led to the insider holds 40,284 shares of the business.
Martin Samuel Bates sold 17,172 shares of CLDX for $608,315 on Jun 14 ’24. The SVP AND CFO now owns 28,125 shares after completing the transaction at $35.42 per share. On Jun 14 ’24, another insider, Crowley Elizabeth, who serves as the SR. VP & CPDO of the company, sold 30,000 shares for $34.87 each. As a result, the insider received 1,045,962 and left with 9,074 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 175.38 while its Price-to-Book (P/B) ratio in mrq is 1.89.
Stock Price History:
Over the past 52 weeks, CLDX has reached a high of $47.00, while it has fallen to a 52-week low of $14.40. The 50-Day Moving Average of the stock is 4.67%, while the 200-Day Moving Average is calculated to be -22.91%.
Shares Statistics:
A total of 66.38M shares are outstanding, with a floating share count of 64.51M. Insiders hold about 2.84% of the company’s shares, while institutions hold 109.41% stake in the company.
